



Primary Peptides

DISCOVERIES FOR MEDICINE



Company Overview

Company Overview



Company Background

- A leading biotech company founded in 2013 by world-class scientists and experienced businessmen
- Capitalizing on the extensive knowledge of human diseases and proteomics amongst its founders and collaborators
- Focusing on innovative peptide drugs using protected platform technology
 - Platform 1: Peptide Array
 - Platform 2: Peptide-mediated Protein Knockdown Technology
- Has identified a series of key domains of disease-related proteins and designed many effective lead compounds
- Patents filed nationally and internationally for 4 lead compounds and 1 platform technology

World-class Founders

- **Dr. Max S. Cynader**, CM, OBC, PhD, FRSC, FCAHS: Founder of 4 start-ups; First company, NeuroVir, was sold to Medigene AG for 140 million
- **Dr. Yu Tian Wang**, MD, PhD, FRSC: Co-founder of NoNO Inc, a peptide therapeutics company with a peptide product currently in phase 3 clinical trial
- **Dr. William Jia**, MSc, PhD: Founder and CSO of several high-tech companies


Verified Platform Technology

- With the same platform technologies, one of the company founders has previously designed a peptide drug that is similar to our company's current patented lead compounds: similar design, similar size, similar drug characteristics, but different targets
- The peptide drug has now entered a phase 3 clinical trial in Canada and the US

Successful Experience

- Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, has signed an **exclusive license** with privately held Primary Peptides, Inc., to develop and commercialise the innovative product K13 targeting PTEN nuclear translocation for the treatment of stroke
- Plan to file IND in 2017 for clinical trials in both Australia and China

Focusing on severe diseases with large drug markets



Lead Compound Characteristics

Drug Category

- **US FDA:** Biotechnology-Derived Pharmaceuticals
- **China CFDA:** Chemical Drug Type 1.1: Synthetic or semi-synthetic chemical drug that is not on the market anywhere

Drug Advantages

- Low toxicity, high specificity, able to cross the blood-brain barrier

Drug Form

- Dry peptide powder

Drug Source

- Chemical synthesis

Company Overview



Investment Highlights

- 1 Respected and experienced founders
- 2 Have signed an exclusive licensing deal with a major Chinese pharmaceutical company
- 3 Robust patent position plus trade secrets
- 4 Disruptive, scalable technologies applied to major diseases. Lead compounds already developed and optimized
- 5 Launch preclinical studies of 6 lead compounds in 3 years; Expect 2 drugs in clinical trials in 2 years
- 6 Large opportunities. Platform technology allows us to rapidly develop plausible leads in new diseases and for new targets
- 7 Globally integrated R&D capabilities and a robust and growing product pipeline

Primary Peptides is looking for 1) additional pharma/biotech partners for drug development and 2) potential investors

If you have any questions, feel free to contact us:



Dr. Max S. Cynader, CM, OBC, PhD, FRSC, FCAHS

Co-founder

Office: (+1) 604-822-0395

Mobile: (+1) 604-649-2274

Email: cynader@brain.ubc.ca

2211 Wesbrook Mall,

Vancouver, BC, Canada, V6T 2B5

www.primarypeptides.com